Edition:
United Kingdom

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

118.20GBp
17 Jan 2018
Change (% chg)

-0.80 (-0.67%)
Prev Close
119.00
Open
119.00
Day's High
119.40
Day's Low
117.10
Volume
1,030,579
Avg. Vol
3,201,629
52-wk High
166.97
52-wk Low
86.50

Select another date:

Thu, Jan 4 2018

BRIEF-Vectura Group Anticipates FY 2017 Revenue In Line With Board's Expectations

* FULL YEAR 2017 REVENUE ANTICIPATED TO BE IN LINE WITH BOARD'S EXPECTATIONS

BRIEF-Vectura group announces buyback to return up to £15 million of capital to shareholders​

* ‍vectura group plc (lse: vec) ("vectura", " group"), announces that board has approved a share buyback to return up to £15 million of capital to shareholders​ Source text for Eikon: Further company coverage: (Reporting by Lawrence White)

BRIEF-Vectura confident on outlook for Novartis inhaler products

* Q3 2017 net sales of $101 million for ultibro ® breezhaler ® and $37 million for seebri ® breezhaler​

BRIEF-Vectura updates on positive Flutiform K-haler regulatory progress

* ‍FLUTIFORM BREATH-ACTIVATED K-HALER MAKES POSITIVE EUROPEAN REGULATORY PROGRESS​

BRIEF-Vectura Group posts HY revenue of 78.8 million pounds

* HY REVENUE 78.8 MILLION POUNDS VERSUS 73.9 MILLION POUNDS A YEAR AGO

BRIEF-Vectura signs VR410 agreement with Pulmatrix

* PROGRESSING DEVELOPMENT OF BRANDED GENERIC TIOTROPIUM BROMIDE PROGRAMME (VR410) FOR US MARKET, ACCELERATED THROUGH LICENCE DEAL WITH PULMATRIX

BRIEF-Vectura announces ANDA filing for US generic version of Advair Diskus

* CONFIRMS STATEMENT MADE BY PARTNER HIKMA IN RESPECT OF ANDA FILING FOR A US GENERIC VERSION OF ADVAIR DISKUS SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE:

Select another date: